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Available online 23 June 2016Metabolic imaging of brain tumors using 13C Magnetic Resonance Spectroscopy (MRS) of hyperpolarized [1-13C]
pyruvate is a promising neuroimaging strategywhich, after a decade of preclinical success in glioblastoma (GBM)
models, is nowentering clinical trials inmultiple centers. Typically, the presence ofGBMhas been associatedwith
elevated hyperpolarized [1-13C] lactate produced from [1-13C] pyruvate, and response to therapy has been asso-
ciated with a drop in hyperpolarized [1-13C] lactate. However, to date, lower grade gliomas had not been inves-
tigated using this approach. Themost prevalentmutation in lower grade gliomas is the isocitrate dehydrogenase
1 (IDH1) mutation, which, in addition to initiating tumor development, also induces metabolic reprogramming.
In particular, mutant IDH1 gliomas are associated with low levels of lactate dehydrogenase A (LDHA) andmono-
carboxylate transporters 1 and 4 (MCT1, MCT4), three proteins involved in pyruvate metabolism to lactate. We
therefore investigated the potential of 13C MRS of hyperpolarized [1-13C] pyruvate for detection of mutant
IDH1 gliomas and for monitoring of their therapeutic response.We studied patient-derivedmutant IDH1 glioma
cells that underexpress LDHA, MCT1 and MCT4, and wild-type IDH1 GBM cells that express high levels of these
proteins. Mutant IDH1 cells and tumors produced signiﬁcantly less hyperpolarized [1-13C] lactate compared to
GBM, consistent with their metabolic reprogramming. Furthermore, hyperpolarized [1-13C] lactate production
was not affected by chemotherapeutic treatment with temozolomide (TMZ) in mutant IDH1 tumors, in contrast
to previous reports in GBM. Our results demonstrate the unusual metabolic imaging proﬁle of mutant IDH1 gli-
omas, which, when combined with other clinically available imaging methods, could be used to detect the pres-
ence of the IDH1 mutation in vivo.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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lenging (McKnight, 2004).
In an effort to address some of these challenges, multiple metabolic
imaging stragegies have been developed (Chaumeil et al., 2015a;
Chronaiou et al., 2014; Golman et al., 2006; Nelson et al., 2013b). In par-
ticular, 1H MR spectroscopy (MRS), which can non-invasively assess
steady-state metabolite levels, has been successfully used in the clinical
setting to complement the anatomic and structural information gener-
ated by MRI, improving clinical practice (McKnight, 2004; Nelson,
2003). Over the past decade, an additional technique named 13C MRS/
spectroscopic imaging (MRSI) of hyperpolarized compounds has also
shown great promise in preclinical studies (for reviews see references
(Brindle et al., 2011; Chaumeil et al., 2015b; Kurhanewicz et al.,
2011)). This imaging strategy, based on the dissolution dynamic nuclear
polarization (DNP) method (Ardenkjaer-Larsen et al., 2003), increases
the MR detectable signal-to-noise ratio (SNR) of hyperpolarized 13C-la-
beled probes by over 10,000 fold, enabling direct monitoring of their
metabolism in real time by 13C MRS and MRSI. The conversion of
hyperpolarized [1-13C] pyruvate to [1-13C] lactate catalyzed by the en-
zyme lactate dehydrogenase A (LDHA) has been themost commonly in-
vestigated reaction in oncology (Brindle et al., 2011; Chaumeil et al.,
2015b; Kurhanewicz et al., 2011), as expression of LDHA is dramatically
increased in most cancer types, associated with the “Warburg effect”
(Warburg, 1956). In neuro-oncology, increased hyperpolarized [1-13C]
lactate production linked to overexpression of LDHA has been used for
tumor detection in several preclinical murine models of glioblastoma
(GBM) (Chaumeil et al., 2012; Park et al., 2011b; Park et al., 2010;
Park et al., 2014; Venkatesh et al., 2012b; Ward et al., 2010a). Further-
more, this method was also shown to enable early imaging of response
to targeted therapies and chemotherapy in GBM. A decrease in the
hyperpolarized lactate-to-pyruvate ratio was observed in GBM cells fol-
lowing treatment with inhibitors of the phosphoinositide 3-kinase/
mammalian target of rapamycin (PI3K/mTOR) pathway. It was correlat-
edwith a drop in LDHA activity, mRNA, and protein levels (Venkatesh et
al., 2012b;Ward et al., 2010a) and this ﬁndingwas further conﬁrmed in
vivo in orthotopic GBM tumors in rats (Chaumeil et al., 2012). Temozo-
lomide (TMZ), the standard of care chemotherapeutic agent for GBM,
was also shown to induce an early decrease in the hyperpolarized
lactate-to-pyruvate ratio in orthotopic GBM models, alone (Park et
al., 2011b; Park et al., 2014) or in combination with PI3K pathway in-
hibitors (Radoul et al., 2016). Importantly, the ﬁrst in-man Phase I
clinical trial of the technology was performed in 2013, and demon-
strated that 13C MRSI of hyperpolarized [1-13C] pyruvate could be
successfully used for tumor detection in prostate cancer patients
(Nelson et al., 2013b). Several other trials, including ones for brain
tumor patients, are now underway in many sites across the world
(clinicaltrials.gov).
Despite the increased interest in translating the DNP-MR strategy to
the clinical neuro-oncological setting, no preclinical studies have
assessed the value of 13C MRS of hyperpolarized [1-13C] pyruvate in
lower grade gliomas, which we now understand differ both genetically
andmetabolically fromprimaryGBM(Goodenberger and Jenkins, 2012;
Huse et al., 2011). Primary Grade IV GBM are associated with multiple
genetic alterations including EGFR ampliﬁcation and TP53, PTEN, and
RB1mutation/loss (Cancer Genome Atlas Research, 2008). From a met-
abolic perspective, GBM tumors overexpress the LDHA enzyme, which
catalyzes the pyruvate to lactate conversion (Cancer Genome Atlas
Research, 2008), and increase the expression of the monocarboxylate
transporters 1 and 4 (MCT1 and MCT4), which control cellular inﬂux
of pyruvate and efﬂux of lactate (Enerson and Drewes, 2003;
Halestrap, 2012; Izumi et al., 2003; Parks et al., 2013; Pinheiro et al.,
2012). In contrast, in lower grade Grade II and III oligodendroglioma
and astrocytoma, as well as in secondary upgraded GBM, up to 90% of
tumors harbor a mutation in the isocitrate dehydrogenase 1 (IDH1) en-
zyme (Cancer GenomeAtlas ResearchN et al., 2015; Parsons et al., 2008;
Yan et al., 2009). Mutant IDH1 catalyzes the reduction of α-ketoglutarate (α-KG) to 2-hydroxyglutarate (2-HG), resulting in non-
physiological levels of this oncometabolite that induces epigenetic per-
turbations and ultimately leads to tumorigenesis (Dang et al., 2009;
Yang et al., 2012). Importantly, the IDH1 mutation also leads to a
broad and unusual reprogramming of cellular metabolism
(Chesnelong et al., 2014; Elkhaled et al., 2014; Esmaeili et al., 2014;
Grassian et al., 2014; Izquierdo-Garcia et al., 2014; Izquierdo-Garcia
et al., 2015b; Ohka et al., 2014; Reitman et al., 2014; Reitman et al.,
2011; Tonjes et al., 2013). By investigating clinically derived samples
and cell models, we demonstrated that the genes coding for LDHA
(LDHA), MCT4 (SLC16A3) and MCT1 (SLC16A1), that are typically
overexpressed in GBM, are silenced or underexpressed in IDH1 mu-
tant gliomas (Chesnelong et al., 2014; Luchman et al., 2012;
Viswanath et al., 2016), suggesting an atypical pyruvate metabolism
in these tumors.
We therefore decided to investigate the value of 13C MRS of
hyperpolarized [1-13C] pyruvate for tumor detection and monitoring
of therapeutic response in this tumor type. To do so, we investigated a
recently developed patient-derived model of Grade III mutant IDH1
oligoastrocytoma, in which LDHA, MCT4 and MCT1 were shown to be
underexpressed (Chesnelong et al., 2014; Viswanath et al., 2016). We
also studied a previously established GBM cell line in which LDHA,
MCT4 and MCT1 are readily detectable. Our metabolic imaging results
show that hyperpolarized [1-13C] lactate levels were barely detectable
in mutant IDH1 glioma neurospheres and tumors, in contrast to the
high levels detected in GBM. Furthermore, we found that TMZ treat-
ment did not induce any signiﬁcant changes in hyperpolarized [1-13C]
lactate levels in mutant IDH1 tumors, even though this therapeutic ap-
proach led to signiﬁcant tumor shrinkage and increased survival. Con-
sidering the increasing translation of 13C MRS of hyperpolarized
[1-13C] pyruvate to the clinic, our ﬁndings are highly signiﬁcant for the
proper interpretation of DNP-MR imaging data from brain tumor pa-
tients and point to an unexpected metabolic imaging signature of mu-
tant IDH1 tumors. 13C MRS of hyperpolarized [1-13C] pyruvate must
thus be used strategically to interrogate tumor type alongside other im-
aging modalities.
2. Material & methods
2.1. Cell models and culture
BT142 cells (Grade III oligoastrocytoma) were cultured as
neurospheres in serum free NeuroCult NS-A Basal Medium (Stemcell
technologies, Vancouver, BC) supplemented with 2 μg·mL−1 Heparin
Solution (Stemcell technologies, Vancouver, BC), 20 ng·mL−1 EGF
(Peprotech, Rocky Hill, NJ), 20 ng·mL−1 FGF (Peprotech, Rocky Hill,
NJ), and 100 ng·mL−1 PDGF (BT142 only, Peprotech, Rocky Hill, NJ)
(Chesnelong et al., 2014). U87 GBMcells were cultured as exponentially
growingmonolayers in high glucoseDulbecco'sModiﬁed EagleMedium
(DMEMH-21, UCSF Cell Culture Facility, San Francisco, CA) supplement-
ed with 10% heat-inactivated fetal bovine serum (Thermo Scientiﬁc
Hyclone, Logan, UT), 2 mM L-Glutamine, 100 u·mL−1 penicillin, and
100 mg·mL−1 streptomycin (UCSF Cell Culture Facility, San Francisco,
CA). All cell lines were maintained at 37 °C in a humidiﬁed atmosphere
of 95% air and 5% CO2.
2.2. Perfusion system
ForMRS studies of live cells,mutant IDH1 glioma cells (n=3BT142)
were encapsulated in agarose beads and GBM cells (n= 3 U87) grown
on microcarrier beads (NUNC) (Chesnelong et al., 2014; Venkatesh et
al., 2012b; Ward et al., 2010a). After 24 h, ~3 × 107 cells were loaded
into a 10-mm NMR tube and connected to a perfusion system
(Chesnelong et al., 2014; Venkatesh et al., 2012b; Ward et al., 2010a).
Brieﬂy, an atmosphere of 5% CO2/95% air was maintained in the perfu-
sion system, and growth medium was circulated through the cells at a
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line allowed for injection of the hyperpolarized pyruvate solution, dur-
ingwhich time the perfusionwas brieﬂy stopped. Prior to and following
each injection of hyperpolarized material, cell viability was conﬁrmed
by recording 31P MR spectra. All experiments were performed at 37 °C.
2.3. Tumor bearing animals
The Institutional Animal Care and Use Committee of the University
of California, San Francisco, approved all animal research. Athymic
mice (BT142: Fox Chase SCID n = 5; U87: rnu/rnu homozygous n =
5; average weight 28 g; female; 6-week old at the time of intracranial
injection; Charles River Laboratories, Wilmington, MA) were used. An
hour before intracranial injection, BT142 or U87 cells were washed
once with PBS, dissociated into single cells by trituration, counted and
resuspended in NeuroCult NS-A Basal medium (BT142, Stemcell tech-
nologies, Vancouver, BC) or Dulbecco's Modiﬁed Eagle Medium (U87,
DMEM H-21, UCSF Cell Culture Facility, San Francisco, CA) to a concen-
tration of 1 × 105 cells per 3 μL. For intracranial injection, mice were
anesthetized by intraperitoneal injection of ketamine/xylazine (100/
20 mg·kg−1). A volume of 3 μL of cell suspension was slowly injected
into the right putamen using the freehand technique (Chaumeil et al.,
2013; Chaumeil et al., 2012; Chesnelong et al., 2014). Buprenorphine
(0.05 mg·kg−1, V = 200 μL) and bupivacaine (5 mg·kg−1, V = 50 μL)
were injected subcutaneously before tumor cell injection and subse-
quent doses given at later time points according to veterinary recom-
mendations in order to ensure optimal pain management.
For in vivo imaging studies, mice were anesthetized using isoﬂurane
(1.5% in O2, 1.5 L·min−1) and a 27G catheter was secured in the tail-
vein for injection of hyperpolarized material. During each MR session,
temperature and respiration rates were continuously monitored and
kept within a constant range to ensure animal well-being and to mini-
mize the potential effect of isoﬂurane anesthesia on themetabolic mea-
surements (Josan et al., 2013) (respiration: 80±10 breaths perminute;
temperature 37.0 ± 0.4 °C).
2.4. Temozolomide treatment
Once the tumor reached a size of ~100 mm3 as assessed from T2-
weighted MR images, BT142 tumor-bearing animals were treated with
4ml.kg−1 TMZ (n=3; SigmaAldrich, St. Louis, MO) in Ora-Plus vehicle
(Perrigo, Dublin, Ireland) by oral gavage at a dose of 5 mg·kg−1 (v =
150 μL per dose). TMZ was given once daily Monday to Friday for up
to 70 days, after which time animals were euthanized.
2.5. Hyperpolarized [1-13C] pyruvate
A volume of 6 μL (for cells) or 24 μL (for animals) of [1-13C] pyruvate
(14.1 M neat, 15 mMOX63 radical, 0.4 mMDotarem)was polarized for
~1 h using a hypersense polarizer (Oxford Instruments) (Chaumeil et
al., 2013; Chaumeil et al., 2012; Chesnelong et al., 2014; Park et al.,
2014; Venkatesh et al., 2012a; Ward et al., 2010a). Hyperpolarized
[1-13C] pyruvate was then rapidly dissolved in isotonic buffer (40 mM
Tris pH = 8, 3.0 μmol·L−1 Na2EDTA for cell studies; 80 mM NaOH,
40 mM Tris pH = 8, 3.0 μmol·L−1 Na2EDTA for animal studies). For
cell studies, a volume of 3 mL of hyperpolarized [1-13C] pyruvate was
injected over 5 s to a ﬁnal concentration of 5 mM. For animal studies,
a volume of 300 μL of the 80 mM hyperpolarized [1-13C] pyruvate solu-
tion was injected in the tail vein catheter over 12 s.
2.6. MR data acquisition in perfused cells
For cell studies, dynamic sets of hyperpolarized 13C spectra were ac-
quired on an 11.7 T INOVA high-resolution spectrometer (Agilent Tech-
nologies, Palo-Alto, CA) starting at the beginning of the pyruvate
injection using a pulse-acquire sequence (13° ﬂip angle (FA), 3 srepetition time (TR), total acquisition time Tacq = 300 s) (Chaumeil
et al., 2013; Chesnelong et al., 2014; Ward et al., 2010a). 31P MR spectra
were acquired prior to and following 13C MRS using a pulse-acquire se-
quence (proton-decoupled, 30° FA, TR = 3 s, spectral width SW =
10 kHz, 10,000 points, number of transients NT = 500) (Chesnelong
et al., 2014; Venkatesh et al., 2012b; Ward et al., 2010a).
2.7. In vivo MR data acquisitions
All in vivo MR experiments were conducted on a mouse-dedicated
14.1 TMR system equippedwith 100G·cm−1 imaging gradients (Agilent
Technologies, Palo-Alto, CA). For T2-weighted acquisitions, a single chan-
nel 1H volume coil was used (ØI = 40 mm). 13C metabolic imaging was
performed using a dual tune 1H-13C volume coil (ØI = 40 mm).
BT142 tumor-bearing animals (n= 5 controls; n= 3 TMZ treated)
and U87 tumor-bearing animals (n = 5 controls) were used in this
study (n = 13 animals total). When the tumor reached ~100 mm3,
MR acquisitions were initiated. T2-weighted and 13C MRSI post
injection of hyperpolarized [1-13C] pyruvate were conducted. T2-
weighted imagingwas performed to assess tumor size and location lon-
gitudinally using a 2D spin-echo multi-slice sequence with the
following parameters: echo time TE/TR = 20/1200 ms; Field of View
FOV = 30 × 30 mm2; matrix 256 × 256; slice thickness 1 mm; 12
axial slices; number of averages NA= 2; Tacq = 10 min 14 sec.
Formetabolic studies, 2D dynamic 13CMRSI datawere acquired at the
start of the intravenous injection of hyperpolarized [1-13C] pyruvate using
the following parameters: TE/TR = 1.2/60 ms; SW = 2500 Hz; 128
points; 4 s temporal resolution; 3.4 mm in-plane resolution; FA 10 deg.;
matrix 128 × 7 × 7; FOV 24 × 24 mm; 5 mm slice thickness; scan time
2.9 s per time points; 16 time points; Tacq= 48 s (Sukumar et al., 2012).
2.8. MR data analysis
Tumor size was measured from the T2-weighted MR images using
the in-house SIVIC software, as previously described (Chaumeil et al.,
2012; Nelson, 2001). Manual contouring of the tumor was performed
in each axial slice, and the ﬁnal volume was automatically calculated
as the sum throughout slices of the tumor area times the slice thickness.
For spectroscopic data, all spectral assignments were based on liter-
ature reports (e.g. www.hmdb.ca). The integrals of hyperpolarized
[1-13C] pyruvate and hyperpolarized [1-13C] lactate were quantiﬁed by
peak integration of the dynamic hyperpolarized 13C spectra using
ACD/Spec Manager 9 (for cell studies) (Chesnelong et al., 2014;
Venkatesh et al., 2012a; Ward et al., 2010a) or using the SIVIC software
(for in vivo studies) (Chaumeil et al., 2013; Chaumeil et al., 2012;
Chesnelong et al., 2014). For further quantiﬁcation of cell and in vivo ex-
periments, the area under the curve (AUC) of the dynamic signal of
hyperpolarized [1-13C] lactate and hyperpolarized [1-13C] pyruvate were
computed, and the ratio of the AUC of hyperpolarized [1-13C] lactate to
hyperpolarized [1-13C] pyruvate (lactate/pyruvate) was calculated for
each voxel of interest (VOI). For evaluation of substrate levels in each
tumor type, hyperpolarized [1-13C] pyruvate levels were calculated from
the tumor VOI and from a VOI containing the major blood vessels in the
animal neck. The ratio between the hyperpolarized [1-13C] pyruvate
levels (AUC) in those two regions was then calculated for each animal
in order to compensate for variability in intravenous injections.
2.9. Western blotting analysis
One hour after the end of the last hyperpolarized 13C MR experi-
ment, untreated animals (n = 5 BT142, n = 5 U87) were euthanized.
Brains were resected and rapidly dissected to isolate the tumor from
the normal brain tissue. Tumorswere then quickly snap-frozen in liquid
N2 and kept at−80 °C until further processing. Tumor tissueswere later
lysed using lysis buffer (Cell Signaling Technology) in the presence of
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~1 × 106 cells were lysed using the same procedure.
For both cells and tumor lysates, Bradford analysis was ﬁrst per-
formed to assess protein content. Denatured proteinswere then electro-
phoresed on 10%BioradReady gels (Life Science Research, Hercules, CA)
using the SDS-PAGEmethod and electrotransferred onto polyvinylidene
ﬂuoride membranes (n = 3 for each cell line and each tumor type).
Blots were probed for LDHA (dilution 1:100, Abcam, Cambridge, MA),
MCT1 (dilution 1:400, Abcam, Cambridge, MA), MCT4 (dilution 1:400,
Abcam, Cambridge, MA), and β-tubulin (dilution 1:1000, Cell Signaling
Technology, Danvers, MA) and visualized using an enhanced chemilu-
minescence kit (ThermoFisher Scientiﬁc, Waltham, MA). Bands were
quantiﬁed using the ImageJ software (NIH) and normalized to β-
tubulin.
2.10. Statistical analysis
All results are expressed as mean± standard deviation. For the sur-
vival study, survival probabilities were calculated according to the
Kaplan–Meier method and compared with the log-rank test. For all
other experiments, two-tailed Student t-test was used to determine
the statistical signiﬁcance of the results. A p-value below 0.05 was con-
sidered signiﬁcant (*p b 0.05; **p b 0.01; ***p b 0.005).
3. Results
3.1. Unlike in GBM cells, hyperpolarized [1-13C] lactate production is not el-
evated inmutant IDH1 glioma cells, associatedwith LDHA,MCT1 andMCT4
silencing
First we conﬁrmed that our BT142 cells reduced expression of LDHA,
MCT1 and MCT4, as previously reported by others (Chesnelong et al.,Fig. 1. Unlike in GBM cells, hyperpolarized [1-13C] lactate production is not elevated in mutant
lactate dehydrogenase A (LDHA), monocarboxylate transporter 1 and 4 (MCT1, MCT4) for BT1
plot of hyperpolarized 13C MR spectra obtained at 11.7 T following injection of hyperpolarized
Production of hyperpolarized [1-13C] lactate could be detected at δ = 185 ppm (see insert)
BT142 (n= 3) and U87 (n= 3) cells, showing the signiﬁcantly lower level of lactate in muta
that the hyperpolarized [1-13C] lactate-to-pyruvate area-under-the-curve (AUC) was 97 ± 3%2014; Viswanath et al., 2016). Western blot analysis showed that
LDHA and MCT4 were virtually silenced in BT142 cells, whereas both
proteins were highly detectable in U87 cells (Fig. 1A; LDHABT142 =
1 ± 1% of U87; MCT4BT142 = 1 ± 1% of U87; n = 3 for each cell line;
***p b 0.005). MCT1 expressionwas signiﬁcantly lower in BT142mutant
IDH1 glioma cells as compared to U87GBMcells, albeit to a lesser extent
(Fig. 1A; MCT1BT142 = 81 ± 5% of U87; n = 3 for each cell line;
**p b 0.01).
Following injection of hyperpolarized [1-13C] pyruvate (δ =
172.9 ppm) into the medium of live U87 GBM cells and BT142 mutant
IDH1 glioma neurospheres, production of hyperpolarized [1-13C] lactate
could be detected at 185 ppm. An example of 13C spectral stack plot ob-
tained in BT142 perfused cells is shown in Fig. 1B. However, when
assessing the ratio of hyperpolarized [1-13C] lactate to pyruvate AUC
for each cell type, our analysis showed that the hyperpolarized lactate/
pyruvate AUC ratio was signiﬁcantly lower (97 ± 3%) in mutant IDH1
cells as compared to GBM cells, as shown in Fig. 1C & D. (***p b 0.005).
3.2. Hyperpolarized [1-13C] lactate production is not elevated in mutant
IDH1 glioma tumors in vivo, in contrast to results in GBM tumors, and is as-
sociated with low LDHA and MCT4 expression
Next, we used 13CMRSI of hyperpolarized [1-13C] pyruvate in vivo to
monitor orthotopic U87 and BT142 tumors in mice.
BT142 and U87 orthotopic tumors were readily detectable using T2-
weighted MR imaging as illustrated in Fig. 2A. BT142mutant IDH1 glio-
ma tumors reached 100mm3 in 95±12 days post intracranial injection
whereas U87GBM tumors reached the same size at 19± 6 days, consis-
tent with the slower growth of lower grade mutant IDH1 tumors com-
pared to GBM in patient data (Chung et al., 2015).
We then investigated hyperpolarized [1-13C] lactate production
from hyperpolarized [1-13C] pyruvate. As shown in Fig. 2A & B, and inIDH1 glioma cells, associated with LDHA, MCT1 and MCT4 silencing (A) Western blots for
42 and U87 glioma cells and corresponding protein levels expressed as % of U87. (B) Stack
[1-13C] pyruvate (δ = 172.9 ppm) in the medium of perfused BT142 IDH1-mutant cells.
. (C) Hyperpolarized [1-13C] lactate signal-to-noise ratio (SNR) as a function of time for
nt IDH1 gliomas as compared to glioblastoma. (D) Quantitative analysis of demonstrates
lower in BT142 compared to U87 cells (n= 3 for each cell line, ***p b 0.005).
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al., 2011b; Park et al., 2010; Park et al., 2014; Venkatesh et al., 2012a;
Ward and Thompson, 2012), high levels of hyperpolarized [1-13C] lac-
tate could be detected in U87 GBM tumors. In contrast, production of
hyperpolarized [1-13C] lactate in BT142 gliomas was barely above
noise level. When comparing the two tumor types, our analysis showed
a signiﬁcantly lower (17 ± 7% of U87) level of hyperpolarized [1-13C]
lactate in BT142 tumors as compared to U87 GBM (Fig. 2C,
hyperpolarized Lactate/PyruvateAUCBT142 = 0.08 ± 0.03 vs. Lactate/
PyruvateAUCU87 = 0.48 ± 0.03; *p= 0.02), consistent with our results
in perfused cells.
As shown in Fig. 2D,MCT1 levels were highly variable and not signif-
icantly different between U87 and BT142 tumors, (MCT1BT142 = 185±
104% of U87; p N 0.05). However, in line with our cell results, MCT4 and
LDHAwere virtually silenced in BT142 tumors, in contrast to high levels
of expression detected in U87 GBM (***p b 0.005; Fig. 2D & E).3.3. Hyperpolarized [1-13C] pyruvate levels are comparable between BT142
mutant IDH1 gliomas and U87 GBM tumors
Pyruvate transport into the cell is mediated primarily by MCT1 but
also by MCT4 (Enerson and Drewes, 2003; Halestrap, 2012; Izumi et
al., 2003; Parks et al., 2013; Pinheiro et al., 2012). We therefore wanted
to rule out reduced hyperpolarized pyruvate delivery to the tumor as an
explanation for the low levels of hyperpolarized lactate production ob-
served in our mutant IDH1 tumor. To do so, we measured the levels of
hyperpolarized pyruvate that reached the tumor VOI for both gliomas.
As shown in Fig. 3, the level of hyperpolarized [1-13C] pyruvate that
reached the tumor VOI was not signiﬁcantly different between U87
and BT142 animals (AUC PyruvateBT142NdBlood = 103 ± 35; AUC
PyruvateU87NdBlood = 85 ± 21; p = 0.38). This result demonstrates a
comparable substrate level in situ, and suggests that substrate availabil-
ity did not play amajor role in the observed difference inhyperpolarized
[1-13C] lactate production observed between BT142 and U87 tumors.Fig. 2. Hyperpolarized [1-13C] lactate production is not elevated in mutant IDH1 glioma tumors
expression (A) T2-weighted MR images of BT142 (left) and U87 (right) tumor bearing mice an
Corresponding stack plot of hyperpolarized 13C MR spectra obtained at 14.1 Tesla following i
hyperpolarized [1-13C] lactate could be detected in both tumor types at δ= 185 ppm, althoug
U87. The color spectra represent the sum of the spectra over time (U87 red; BT142 blue). (B
n= 5) and a BT142 (blue, n= 5) tumor voxels. (C) Analysis of the ratios of hyperpolarized [1
of hyperpolarized [1-13C] lactate production in BT142 tumors as compared to U87 (*p b 0.05).
and 4 (MCT1, MCT4) for BT142 and U87 tumor lysates and (E) corresponding protein levels ex3.4. TMZ treatment leads to tumor shrinkage and improved survival, but
does not induce a change in hyperpolarized [1-13C] lactate production in
mutant IDH1 glioma in vivo
Finally, we wanted to assess whether hyperpolarized [1-13C] lactate
production, which was previously shown to be altered by TMZ treat-
ment in GBM, would be affected in any way by TMZ treatment in mu-
tant IDH1 tumors. Our anatomic imaging showed that TMZ treatment
induced a signiﬁcant decrease in tumor size starting at day 14 of treat-
ment, and ultimately led to a complete disappearance of the tumor on
the T2-weightedMR images (after day 62, n=3, Fig. 4A). Furthermore,
TMZ treatment signiﬁcantly increased the survival of BT142 tumor-
bearing animals, as shown in Fig. 4B (χ2= 86.07; ***p b 0.005). Howev-
er, in contrast to ﬁndings in GBM, our results show that the
hyperpolarized [1-13C] lactate-to-pyruvate ratio in the tumor voxel
remained unchanged during the course of TMZ therapy (Fig. 4C & D,
p N 0.04 for all time points).4. Discussion
This study investigated the value of hyperpolarized 13C MRS for de-
tecting mutant IDH1 tumors and their response to treatment. We
compared ﬁndings from the recently isolated, clinically-derived BT142
grade III mutant IDH1 model, to observations in a previously established
primaryGrade IVGBMmodel. Unlike pairs of genetically-engineeredmu-
tant andwild-type IDH1-expressing cells used in prior studies (Chaumeil
et al., 2014; Chaumeil et al., 2013; Izquierdo-Garcia et al., 2014;
Izquierdo-Garcia et al., 2015a; Izquierdo-Garcia et al., 2015b), this ap-
proach precludes a direct comparison between wild-type and mutant
IDH1-associated events. However, it should be noted that an in vivo com-
parison between genetically engineered mutant and wild-type IDH1-ex-
pressing tumors is not straightforward.Mostwild-type IDH1 cells that do
not harbor additional genetic alterations (including the commonly used
immortalized human astrocyte model (Izquierdo-Garcia et al., 2014;in vivo, in contrast to results in GBM tumors, and is associated with low LDHA and MCT4
d positioning of tumor voxels (U87 red; BT142 blue). The tumor is circled in dashed lines.
ntravenous injection of hyperpolarized [1-13C] pyruvate (δ = 172.9 ppm). Production of
h the levels of hyperpolarized [1-13C] lactate was lower in BT142 tumors as compared to
) Kinetics of hyperpolarized (HP) lactate normalized to maximum pyruvate in U87 (red,
-13C] lactate-to-pyruvate AUC in tumor voxels demonstrates the signiﬁcantly lower level
(D) Western blots for lactate dehydrogenase A (LDHA), monocarboxylate transporters 1
pressed as % of U87 (**p b 0.01; ***p b 0.005).
Fig. 3. In vivo hyperpolarized [1-13C] pyruvate levels are comparable between tumor types (A) T2-weightedMR images showing the positioning of voxels of interest (VOI) from the tumor
regions (blue/red) and from a region containing the major blood vessels in the animal neck (green). A BT142 tumor was chosen as an example in this ﬁgure. (B) Analysis of the ratios of
pyruvate AUC in tumor VOI to the corresponding blood VOI demonstrated a comparable level of hyperpolarized [1-13C] pyruvate in BT142 and U87 tumor voxels (N.S.: not signiﬁcant).
185M.M. Chaumeil et al. / NeuroImage: Clinical 12 (2016) 180–189Izquierdo-Garcia et al., 2015a; Izquierdo-Garcia et al., 2015b; Sonoda et
al., 2001)) fail to form tumors in vivo. As a result, previous in vivo compar-
isons have usedmodels engineered fromprimary GBM, and therefore theFig. 4. Temozolomide (TMZ) treatment leads to tumor shrinkage and improved survival, but do
in vivo (A) Evolution of tumor size in control (blue, n = 5) and TMZ-treated (purple, n = 3)
treatment, showing the signiﬁcant tumor shrinkage in TMZ-treated animals as compared to
BT142 tumor-bearing animals induced by TMZ treatment (χ2 = 86.07; ***p b 0.005). (C) T2-
and day 14 (purple, right) post TMZ treatment overlaid with the grid used for hyperpolarized
comparable levels of hyperpolarized lactate and pyruvate pre and post treatment. (D) Analysi
day 0 (n= 3) demonstrates the unchanged level of lactate at days 2, 9 and 14 of TMZ treatmemetabolic ﬁndings could be confounded by events associated with GBM
development. Furthermore, when investigating genetically engineered
models, mutant IDH1-associated reprogramming depends on thees not induce a change in hyperpolarized [1-13C] lactate production inmutant IDH1 glioma
animals as measured from T2-weighted MR imaging as a function of time post start of
controls. (B) Kaplan-Meier survival probability plot showing the increased survival of
weighted MR images of the brain of a BT142 tumor-bearing mouse at day 0 (blue, left)
13C MR spectroscopic imaging. Corresponding 13C spectra from tumor voxels show the
s of the hyperpolarized [1-13C] lactate-to-pyruvate AUC from tumor voxel normalized to
nt.
186 M.M. Chaumeil et al. / NeuroImage: Clinical 12 (2016) 180–189number of passages that cells have been in culture (Turcan et al., 2012),
also potentially limiting the signiﬁcance of results. Here we investigated
patient-derived models while linking our imaging ﬁndings to biological
observations made in these and other models, as well as in The Cancer
Genome Atlas (TCGA) clinical data (Chesnelong et al., 2014; Viswanath
et al., 2016).
From a technical perspective, in our in vivo studies we used a novel
2D dynamic MRSI sequence allowing acquisition of the full
hyperpolarized lactate and pyruvate kinetics. Unlike single time point
sequences, which have been the most commonly used to date, this
type of acquisition limits quantiﬁcation errors due to temporal differ-
ences in the kinetics of substrate and products between different re-
gions of interest, increasing the robustness of the acquired data
(Sukumar et al., 2012). Furthermore, acquisition of dynamic data en-
abled us to conduct our analysis using the AUC ratio, which, as re-
cently described by Daniels et al., performs signiﬁcantly better than
lactate-to-pyruvate ratio at the time of maximum lactate signal,
and produces similar statistical results to any kinetic modeling
Daniels et al. (2016)). Using this sequence and subsequent AUC anal-
ysis, we ﬁrst demonstrated a high lactate-to-pyruvate AUC ratio in
U87 tumors, in line with numerous previous studies on GBMs
(Chaumeil et al., 2012; Park et al., 2011b; Park et al., 2010; Park et
al., 2014; Radoul et al., 2015b). In contrast, in BT142 mutant IDH1
orthotopic tumors, hyperpolarized [1-13C] lactate production was
barely above noise level.
We also wanted to investigate if in situ substrate levels could be
contributing to the detected differences in hyperpolarized [1-13C]
lactate production between tumor types. To do so, ideally one
would want to measure the arterial input function (AIF) for each an-
imal and each injection, similar to Positron Emission Tomography
(PET) studies. However, measuring an AIF in DNP-MR studies re-
mains challenging. It has only been evaluated in a few specialized
studies in vivo, by using an implantable coil in the rat carotid
(Marjańska et al., 2012), quantifying the signal from the injected
hyperpolarized substrate in a catheter adjacent to the coil (Kazan
et al., 2013), or by extrapolation of the data using a gamma-variate
function (von Morze et al., 2011). Here, we used a more simplistic
approach in which we compared the AUC of pyruvate in the tumor
voxel to the same parameter in a voxel containing major neck
blood vessels and no cerebral tissue. This approach, while not an
AIF measurement, helps minimize confounding factors that affect
the signal intensity in the tumor voxel, and in particular polarization
level at the time of injection and inter-study variability in injection
rates. Using this analysis, our results demonstrate a comparable
level of hyperpolarized [1-13C] pyruvate in BT142 and U87 tumor
voxels, ruling out a major effect of substrate availability on the low
hyperpolarized [1-13C] lactate production observed in BT142 tumors.
Our biochemical results conﬁrmed previous studies by Chesnelong
et al. (Chesnelong et al., 2014) and Viswanath et al. (Viswanath et al.,
2016) indicating LDHA and MCT4 silencing in mutant IDH1 BT142 glio-
mas, both in cell lysates and in resected tumor lysates. Additionally, we
showed that MCT1 expression was lower in BT142 cell lysates than in
U87 cell lysates, also in line with the report by Viswanath et al.
(Viswanath et al., 2016). However, this observation did not hold in the
in vivo setting. A possible reason for this is that MCT1 levels were only
19 ± 5% lower in BT142 cells than in U87 cells, as compared to N99%
lower for LDHA and MCT4. It is thus likely that the difference in MCT1
levels between the two tumors was diluted by other cell types within
the brain parenchyma, which typically presents high levels of MCT1
under physiological conditions (Chiry et al., 2006; Gerhart et al., 1997;
Pierre et al., 2000).
LDHA,MCT1 andMCT4 are all involved in pyruvatemetabolism, and
their relative levels have been shown to play important roles in
hyperpolarized [1-13C] lactate production (Brindle et al., 2011;
Chaumeil et al., 2015b; Kurhanewicz et al., 2011). The role of LDHA is
most central, as this enzyme converts pyruvate into lactate. As such,LDHA silencing in mutant IDH1 tumors is entirely consistent with the
low level of hyperpolarized [1-13C] lactate detected in perfused cells
and tumors in this study. When looking at the transporters, MCT4 pri-
marily controls lactate efﬂux, whereas MCT1 mostly participates in py-
ruvate uptake (Enerson and Drewes, 2003; Halestrap, 2012; Izumi et al.,
2003; Parks et al., 2013; Pinheiro et al., 2012). Interestingly, elevated ex-
pression of MCT4 has been linked to lower hyperpolarized [1-13C] lac-
tate production, through a decreased intracellular lactate pool
(Keshari et al., 2013; Sriram et al., 2015). MCT4 silencing in BT142
cells and tumors is thus unlikely to contribute to the lowhyperpolarized
[1-13C] lactate signal. On the other hand, we cannot rule out that the
lower level of MCT1 in BT142 cells could contribute to the subsequent
low production of hyperpolarized [1-13C] lactate. However, in the in
vivo setting, MCT1 levels were not signiﬁcantly different between U87
and BT142 tumors, and hyperpolarized pyruvate levels were compara-
ble, suggesting that the contribution of MCT1 to the differences in
hyperpolarized [1-13C] lactate levels between the tumor types is limit-
ed. It is important to note that, consistent with LDHA silencing, clinical
studies have demonstrated that the steady-state levels of lactate ob-
served by 1H MRS are relatively low in low-grade glioma, the vast
majority of which harbor the IDH1 mutation (Cancer Genome
Atlas Research N, 2008; Parsons et al., 2008; Yan et al., 2009). Pre-
clinical studies have also shown that intracellular lactate levels are
lower in mutant IDH1 expressing cells compared to wild-type
(Izquierdo-Garcia et al., 2015b). A small lactate pool size would, in
turn, further contribute to the low level of hyperpolarized [1-13C]
lactate detected in BT142 tumors (Day et al., 2007). The contribution
of intracellular lactate levels to the production of hyperpolarized
lactate could be assessed in our models using dedicated sequences
such as MAD-STEAM (Larson et al., 2012; Swisher et al., 2014) or
diffusion-weighted DNP-MR (Koelsch et al., 2015). These would
tease apart the respective contributions of the vascular, intracellular
and extracellular compartments to the signal of each hyperpolarized
metabolite. Nonetheless, regardless of the subtilities of the underly-
ing mechanisms, our ﬁndings with regard to low hyperpolarized
[1-13C] lactate levels in vivo in BT142 tumors are likely primarily as-
sociated with LDHA silencing, and demonstrate the highly unusual
imaging proﬁle of this tumor type.
From a therapeutic perspective, a drop in hyperpolarized [1-13C] lac-
tate production has been consistently observed in response to treat-
ment and is currently entering clinical trials as a biomarker of
response in multiple cancer types including glioma (Chaumeil et al.,
2015b; Chaumeil et al., 2012; Nelson et al., 2013a; Park et al., 2011a;
Park et al., 2014; Radoul et al., 2015a; Venkatesh et al., 2012a; Ward et
al., 2010b). We therefore wanted to clearly demonstrate that, unlike in
other cancers, hyperpolarized [1-13C] lactate is unlikely to be infor-
mative of response in mutant IDH1 gliomas. Our study showed that
TMZ treatment induced a dramatic shrinkage of mutant IDH1 tumors
that was associated with a signiﬁcant increase in survival. This is in
line with previous reports of high chemo-sensitivity for mutant
IDH1 glioma (Cairncross et al., 2013), and points to the likely rele-
vance of the BT142 model for assessment of therapeutic approaches
for mutant IDH1 tumors. Furthermore, as expected, our ﬁndings with
regard to using 13C MRS of hyperpolarized [1-13C] pyruvate for
predicting response to therapy were in contrast to previous work
in primary wild-type IDH1 GBM. Previous investigations of GBM
models showed a signiﬁcant decrease in hyperpolarized [1-13C] lac-
tate-to-pyruvate ratio as early as one day post treatment with TMZ
and before any changes in tumor size (Park et al., 2011b; Park et
al., 2014); our study in BT142 tumors shows that hyperpolarized lac-
tate levels remained unchanged during TMZ treatment, even though
tumor size decreased. This result not only demonstrates the unique
metabolic proﬁle of mutant IDH1 tumors following therapy, but
also conﬁrms the need for alternative imaging approaches for early
assessment of drug action and for predicting response to TMZ in mu-
tant IDH1 tumors.
187M.M. Chaumeil et al. / NeuroImage: Clinical 12 (2016) 180–1895. Conclusion
Our results demonstrate that mutant IDH1 gliomas present a highly
unusualmetabolic imaging proﬁle. Unlike any other cancer investigated
to date, this tumor type is characterized by an absence of elevated
hyperpolarized [1-13C] lactate production. On onehand, this study high-
lights the limitation of 13C MRS of hyperpolarized [1-13C] pyruvate as a
method for detection andmonitoring of therapeutic response inmutant
IDH1. On the other hand, the absence of elevated hyperpolarized [1-13C]
lactate can be viewed as a unique feature of mutant IDH1 gliomas. This
imaging strategy could thus be combinedwith other metabolic imaging
approaches such as 1HMRS to detect elevated 2-HG levels (Andronesi et
al., 2012; Choi et al., 2012; Elkhaled et al., 2012; Pope et al., 2012), or
hyperpolarized 13C MRS to monitor elevated [1-13C] 2-HG (Chaumeil
et al., 2013) and reduced [1-13C] glutamate (Chaumeil et al., 2014) syn-
thesis and, collectively, these imageable mutant IDH1-associated meta-
bolic alterations that are detectable by MRS could serve to speciﬁcally
identify mutant IDH1 tumors in patients.
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